SIROS provides a precise, versatile, and straightforward solution for interventional radiologists to deliver patient-tailored care.
FREMONT, CA: Sirtex Medical U.S. Holdings, Inc., a leading manufacturer of targeted liver cancer therapies, announced the launch of SIROS, an innovative system for the delivery of SIR-Spheres® Y-90 resin microspheres.
SIROS offers a visual, versatile, and intuitive option for interventional radiologists to deliver SIR-Spheres® to liver cancer patients. With the visually controlled administration system, physicians can determine and adjust the exact quantity and speed of SIR-Spheres® microspheres delivery. In addition to that, the system is designed to be simple to use yet versatile enough to allow expanded options for patient-tailored delivery.
SIROS intuitive design features a peel-and-place tubing set. It is a proprietary needleless D-Vial specifically designed to suspend SIR-Spheres® into a vortex that may allow for more even distribution, and a locking cover to safely secure the microspheres during delivery. A three-step setup further provides quick and straightforward administration and disposal.
“SIROS brings world-class expertise and innovation together to provide interventional radiologists with the support and technology they need to treat patients with liver cancer,” says Kevin R. Smith, Chief Executive Officer of Sirtex. “As established leaders in the industry for more than 20 years, we are pleased to add SIROS„¢ to our expanding portfolio of technology designed to advance patient care.”
A global healthcare business Sirtex has offices in the U.S., Australia, Europe, and Asia to improve outcomes in people with cancer. Sirtexs current lead product is targeted radiation therapy for liver cancer called SIR-Spheres® Y-90 resin microspheres. More than 100,000 doses have been supplied until today to treat liver cancer patients at more than 1,300 medical centers in over 45 countries.